Evidence map›Paper›PMID 32666202›Full record

ArticleJournal of gastroenterology2020

Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B.

Akihiro Matsumoto, Shuhei Nishiguchi, Hirayuki Enomoto, Yasuhito Tanaka, Noboru Shinkai, Chiaki Okuse, Jong-Hon Kang, Takeshi Matsui, Shiho Miyase, Hiroshi Yatsuhashi and 17 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Efficacy and Safety of PeginterferonContrast media & molecular imaging · 2022
    Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 20 institutions in 1 country.

Akihiro MatsumotoDepartment of Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
Shuhei NishiguchiDivision of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Hirayuki EnomotoDivision of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Yasuhito TanakaDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Noboru ShinkaiDepartment of Virology and Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Chiaki OkuseDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Kawasaki Municipal Tama Hospital, Kawasaki, Japan.
Jong-Hon KangCenter for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Takeshi MatsuiCenter for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan.
Shiho MiyaseDepartment of Gastroenterology and Hepatology, Kumamoto Shinto General Hospital, Kumamoto, Japan.
Hiroshi YatsuhashiThe Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
Shinya NagaokaThe Clinical Research Center, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
Tatsuo KandaDivision of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan.
Masaru EnomotoDepartment of Hepatology, Osaka City University Medical School, Osaka, Japan.
Ryoko YamadaDepartment of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Naoki HiramatsuDepartment of Gastroenterology, Osaka Rosai Hospital, Sakai, Japan.
Satoru SaitoDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.
Koichi TakaguchiDepartment of Hepatology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
Kiyoaki ItoDivision of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Tsutomu MasakiDepartment of Gastroenterology and Neurology, Kagawa University School of Medicine, Kagawa, Japan.
Daisuke MoriharaDepartment of Gastroenterology, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Masataka TsugeDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kazuaki ChayamaDepartment of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Fusao IkedaDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Tatehiro KagawaDivision of Gastroenterology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan.
Yasuteru KondoDepartment of Hepatology, Sendai Kousei Hospital, Sendai, Japan.
Kazumoto MurataDivision of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Shimotsuke, Japan.
Eiji TanakaDepartment for the Promotion of Regional Medicine, Shinshu University School of Medicine, Asahi 3-1-1, Matsumoto, 390-8621, Japan. etanaka@shinshu-u.ac.jp.ORCID http://orcid.org/0000-0002-0724-2104
Hiroshima University · JPHyogo Medical University · JPNagasaki Medical Center · JPNagoya City University · JPShinshu University · JPTeine Keijinkai Hospital · JPAichi Medical University · JPFukuoka University · JPJichi Medical University · JPKagawa Prefectural Central Hospital · JPKagawa University · JPKawasaki Municipal Hospital · JPNihon University · JPOkayama University · JPOsaka City University · JPOsaka Rosai Hospital · JPSendai Kousei Hospital · JPThe University of Osaka · JPTokai University · JPYokohama City University · JP

Funding

The Japan Agency for Medical Research and Development JP18fk0210034The Japan Agency for Medical Reserch and Developement 17fk0210306h003
6 · The paper itself

Abstract

backgroundA prospective pilot study of tenofovir disoproxil fumarate (TDF) and pegylated interferon alpha 2a (P-IFN) add-on therapy was conducted to evaluate its efficacy in reducing viral antigen levels in Japanese patients with chronic hepatitis B (UMIN 000020179).

methodsPatients with chronic hepatitis B receiving maintenance TDF therapy and exhibiting hepatitis B surface antigen (HBsAg) level > 800 IU/ml were divided into two arms. P-IFN was added for 48 weeks in the add-on arm (n = 32), while TDF monotherapy was maintained in the control arm (n = 51). Both groups were followed for 96 weeks after baseline measurements.

resultsAlmost all patients in the control arm displayed a slow and constant reduction in HBsAg during follow-up. In contrast, roughly half of the add-on arm exhibited a sharp decline in HBsAg during P-IFN administration, which disappeared after halting P-IFN. At 96 weeks after baseline, 41% (13/32) of patients in the add-on arm had shown a rapid decrease in HBsAg, versus 2% (1/51) in the control arm (p < 0.001). Add-on therapy and increased cytotoxic T-cell response were significant factors associated with a rapid decrease in HBsAg according to multivariate analysis. In addition, higher HB core-related antigen (HBcrAg) level at baseline (p = 0.001) and add-on therapy (p = 0.036) were significant factors associated with a rapid reduction in HBcrAg.

conclusionsTDF and P-IFN add-on therapy in Japanese patients with chronic hepatitis B facilitated rapid decreases in HBsAg and HBcrAg. Further studies are needed to improve early HBsAg clearance rate.

Indexed as

AdultAntiviral AgentsCohort StudiesDrug Therapy, CombinationFemaleFollow-Up StudiesHepatitis B, ChronicHepatitis B Core AntigensHepatitis B Surface AntigensHumansInterferon-alphaJapanMaleMiddle AgedPilot ProjectsPolyethylene GlycolsAntiviral AgentsHepatitis B Core AntigensHepatitis B Surface AntigensInterferon-alphapeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsTenofovirAdd-on therapyHepatitis B core-related antigenHepatitis B surface antigenPegylated interferonTenofovir

Identifiers

PMID32666202
OpenAlexW3043603892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.